Peer-Reviewed Articles

Scientific Journals

May 2020

Jun Gui, Farima Zahedi, Angelica Ortiz, Christina Cho, Kanstantsin V. Katlinski, Kevin Alicea-Torres, et al. Nature Cancer.

October 2018

Sima Patel, Shuyu Fu, Jerome Mastio, George A. Dominguez, Abhilasha Purohit, Andrew Kossenkov, Cindy Lin, Kevin Alicea-Torres, et al. Nature Immunology.

October 2018

Sushil Kumar, David W. Wilkes, Nina Samuel, Mario Andres Blanco,Anupma Nayak, Kevin Alicea-Torres, et al. Journal of Clinical Investigation.

December 2017

Filippo Veglia, Vladimir A. Tyurin, Dariush Mohammadyani, Maria Blasi, Elizabeth K. Duperret, Laxminarasimha Donthireddy, Ayumi Hashimoto, Alexandr Kapralov, Andrew Amoscato, Roberto Angelini, Sima Patel, Kevin Alicea-Torres, et al. Nature Communications.

August 2016

Thomas Condamine, George A. Dominguez, Je-In Youn, Andrew V. Kossenkov, Sridevi Mony, Kevin Alicea-Torres, et al. Science Immunology.

 

Newspaper Articles

English and Spanish

November 2020

Ciencia, El Nuevo Día Newspaper

August 2020

Ciencia, El Nuevo Día Newspaper

August 2020

Ciencia, El Nuevo Día Newspaper

August 2020

Ciencia, El Nuevo Día Newspaper

 

Chapter Books

2018

Kevin Alicea-Torres & Dmitry I. Gabrilovich. Oncoimmunology. Springer, Cham.
The accumulation of highly immunosuppressive myeloid cells known as myeloid-derived suppressor cells (MDSCs) is one of the immunological hallmarks of cancer. MDSCs are a heterogeneous population of bone marrow-derived immature myeloid cells that accumulate in the blood, peripheral lymphoid organs, and tumor tissues, which correlates with a poor clinical outcome in cancer patients. The main feature of MDSCs is their ability to suppress antitumor responses leading to tumor progression. Thus, MDSCs represent an attractive therapeutic target to enhance antitumor responses in cancer.